• 1
    Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996; 92: 1304.
  • 2
    Broeks A, Urbanus JH, Floore AN et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 2000; 66: 494500.
  • 3
    Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001; 11: 717.
  • 4
    Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000; 1: 17986.
  • 5
    Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998; 1400: 12137.
  • 6
    Alexander FE, Patheal SL, Biondi A et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001; 61: 25426.
  • 7
    Ross JA, Davies SM, Potter JD, Robison LL. Epidemiology of childhood leukemia, with a focus on infants. Epidemiol Rev 1994; 16: 24372.
  • 8
    Ross JA, Potter JD, Robison LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst 1994; 86: 167880.
  • 9
    Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control 1996; 7: 58190.
  • 10
    Broeker PL, Super HG, Thirman MJ et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 1996; 87: 191222.
  • 11
    Oguchi K, Takagi M, Tsuchida R et al. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood 2003; 101: 36227.
  • 12
    Ziv Y, Bar-Shira A, Pecker I et al. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 1997; 15: 15967.
  • 13
    Carpenter AJ, Porter AC. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell 2004; 15: 570011.
  • 14
    Meyer C, Schneider B, Reichel M et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA 2005; 102: 44954.
  • 15
    Blanco JG, Edick MJ, Relling MV. Etoposide induces chimeric Mll gene fusions. FASEB J 2004; 18: 1735.
  • 16
    Kobayashi M, Adachi N, Aratani Y, Kikuchi A, Koyama H. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett 2001; 166: 717.
  • 17
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res 1996; 8: 10110.
  • 18
    Zhou Z, Zwelling LA, Kawakami Y et al. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999; 59: 461824.
  • 19
    Bower JJ, Zhou Y, Zhou T et al. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM. Cell Cycle 2010; 9: 161728.
  • 20
    Caporossi D, Porfirio B, Nicoletti B et al. Hypersensitivity of lymphoblastoid lines derived from ataxia telangiectasia patients to the induction of chromosomal aberrations by etoposide (VP-16). Mutat Res 1993; 290: 26572.
  • 21
    Petrinelli P, Elli R, Marcucci L, Barbieri C, Ambra R, Antonelli A. VP16 hypersensitivity and increased faulty recombination in ataxia telangiectasia lymphocytes characterized by the tandem translocation t(14;14)(q11;q32). Carcinogenesis 1996; 17: 2037.
  • 22
    Smith PJ, Makinson TA. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res 1989; 49: 111824.
  • 23
    Kaufmann WK, Boyer JC, Estabrooks LL, Wilson SJ. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol 1991; 11: 37118.
  • 24
    Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499506.
  • 25
    Mohamed R, Pal Singh S, Kumar S, Lavin MF. A defect in DNA topoisomerase II activity in ataxia-telangiectasia cells. Biochem Biophys Res Commun 1987; 149: 2338.
  • 26
    Singh SP, Lavin MF. Study of DNA topoisomerase II in ataxia-telangiectasia cells. Carcinogenesis 1989; 10: 12158.
  • 27
    Lavin MF, Singh SP. Defective DNA topoisomerase II in ataxia-telangiectasia cells. Acta Biol Hung 1990; 41: 12535.
  • 28
    Davies SM, Harris AL, Hickson ID. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant. Nucleic Acids Res 1989; 17: 133751.
  • 29
    Lou Z, Minter-Dykhouse K, Chen J. BRCA1 participates in DNA decatenation. Nat Struct Mol Biol 2005; 12: 58993.
  • 30
    Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000; 14: 92739.
  • 31
    Yamane K, Tsuruo T. Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA. Oncogene 1999; 18: 5194203.
  • 32
    Yamane K, Wu X, Chen J. A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol Cell Biol 2002; 22: 55566.
  • 33
    Cowell IG, Okorokov AL, Cutts SA et al. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53. Exp Cell Res 2000; 255: 8694.
  • 34
    Wells NJ, Addison CM, Fry AM, Ganapathi R, Hickson ID. Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro. J Biol Chem 1994; 269: 2974651.
  • 35
    Wells NJ, Fry AM, Guano F, Norbury C, Hickson ID. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C. J Biol Chem 1995; 270: 2835763.
  • 36
    Ishida R, Iwai M, Marsh KL et al. Threonine 1342 in human topoisomerase IIalpha is phosphorylated throughout the cell cycle. J Biol Chem 1996; 271: 3007782.
  • 37
    Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK. Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem 2000; 275: 347108.
  • 38
    Wells NJ, Hickson ID. Human topoisomerase II alpha is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur J Biochem 1995; 231: 4917.
  • 39
    Shapiro PS, Whalen AM, Tolwinski NS et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999; 19: 355160.
  • 40
    Bensimon A, Schmidt A, Ziv Y et al. ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. Sci Signal 2010; 3: rs3.
  • 41
    Kim ST, Lim DS, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 1999; 274: 3753843.
  • 42
    Watanabe F, Teraoka H, Iijima S, Mimori T, Tsukada K. Molecular properties, substrate specificity and regulation of DNA-dependent protein kinase from Raji Burkitt's lymphoma cells. Biochim Biophys Acta 1994; 1223: 25560.
  • 43
    Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286: 11626.
  • 44
    Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res 2001; 92: 11337.
  • 45
    Feldhoff PW, Mirski SE, Cole SP, Sullivan DM. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994; 54: 75662.
  • 46
    Wessel I, Jensen PB, Falck J, Mirski SE, Cole SP, Sehested M. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res 1997; 57: 44514.
  • 47
    Oloumi A, MacPhail SH, Johnston PJ, Banath JP, Olive PL. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res 2000; 60: 574753.
  • 48
    Chan VT, Ng SW, Eder JP, Schnipper LE. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J Biol Chem 1993; 268: 21605.
  • 49
    Patel S, Keller BA, Fisher LM. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells. Mol Pharmacol 2000; 57: 78491.
  • 50
    Lee MS, Wang JC, Beran M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 1992; 223: 83743.
  • 51
    Mao Y, Yu C, Hsieh TS et al. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 1999; 38: 10793800.
  • 52
    Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 1991; 51: 527583.
  • 53
    Mirski SE, Cole SP. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 1995; 55: 212934.
  • 54
    Nakada S, Katsuki Y, Imoto I et al. Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. J Clin Invest 2006; 116: 809.